Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

NCT07723469 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: BCS + SRG-514
PROCEDURE: BCS

Sponsor

SURGE Therapeutics